

## **CURRICULUM VITAE**

**Mohamed Aboulfetouh Shehata**

**Professor and head of Clinical Oncology**

**Faculty of medicine**

**Menoufia University**

**MD, FRCR (clinical oncology)**

**Personal data:**

Surname : Shehata  
First name : Mohamed  
Other names : Abouelfetouh  
Title : Dr.  
Date of birth : 6/9/1967  
Qualifications : MBBCh, MSc Oncology,  
MD Clinical Oncology,  
FRCR Clinical Oncology  
Marital status : Married, with two children  
Present address : 2 Abdelkhalek Zanaty st.  
Shebin Elkom  
Menoufia, Egypt  
Departmental address : Menoufia University  
Faculty of Medicine  
Vice Dean for postgraduate studies and research  
Phone numbers : (W) 0482228803 (C) 0482222665  
(M) 01091001255  
E-mail : [mohaboulfetouh@yahoo.com](mailto:mohaboulfetouh@yahoo.com)  
[mohamed.shehata@med.menofia.edu.eg](mailto:mohamed.shehata@med.menofia.edu.eg)  
H Index : 13  
Citations : 692

**Education / Work experience / Awards:*****A) Education***

Autumn 2008 Fellowship of the Royal College of Radiologists  
(FRCR, Clinical Oncology) London , united Kingdom

April 2005 MD in Clinical Oncology, Menoufia University, Egypt

Supervisors: professor . Kamal Elghamrawey (Professor of  
Clinical Oncology, Cairo University)  
Professor Tarek Hashem (Professor of Clinical Oncology,  
Menoufia University)

Topic of project: A Randomized Trial Comparing Neoadjuvant  
Chemotherapy And Reduced Volume Pelvic Radiotherapy Versus  
Neoadjuvant Chemotherapy And Standard Volume Pelvic  
Radiotherapy In Invasive Carcinoma Of Urinary Bladder

October 2000 Master of Clinical Oncology - Menoufia University, Egypt

Topic of project: Detection of bcl translocations in non-Hodgkin's  
lymphoma and its correlation to natural behaviour of the disease  
as well as treatment response  
Main supervisors: professor Dr. Kamal Elghamrawey  
(Professor of Clinical Oncology, Cairo University)  
Professor Dr. Tarek Hashem (Professor of Clinical Oncology)

|                              |   |
|------------------------------|---|
| December 1995                | ECFMG certificate from USA  |
| February 1991                | MBBCh -Faculty of Medicine, Menoufia University, Egypt  |
| <b>B) Work experience</b>    |   |
| 1 August 2024-Ongoing:       | Vice dean for postgraduate studies and research   |
| April 2023- 31-7-2024:       | Head & prof of Clinical oncology department, Faculty of Medicine, Menoufia University   |
| 2022 -ongoing:               | Member of the scientific committee for the presidential initiative for prevention and treatment of cancer   |
| August 2022- april 2023:     | Professor of clinical Oncology  |
| August 2019-August 2022:     | Head & prof of Clinical oncology department, Faculty of Medicine, Menoufia University   |
| July 2016- August 2019:      | Professor in Clinical Oncology, Faculty of Medicine, Menoufia University.   |
| May 2011- July 2016:         | Assistant professor in Clinical Oncology, Faculty of Medicine, Menoufia University.   |
| September 2005- May 2011 :   | 'Lecturer in Clinical Oncology', Faculty of Medicine, Menoufia University.  |
| January 2006-June 2010:      | Research Fellow, Department of Oncology, Nottingham City Hospital, NUH, NHS Trust, Nottingham, United Kingdom.  |
| July 2009- January 2010      | <p>Supervisor: Dr. Stephen Chan, Consultant Oncologist, Nottingham University hospitals, City Hospital campus, Nottingham, United Kingdom.</p> <p>Visiting research clinical oncology specialist registrar (weekly basis), Oncology Centre, addenbrooke's Hospital, Cambridge University hospitals, NHS foundation trust, Cambridge, United Kingdom.</p> <p>Supervisors: Dr Charlotte Coles and Dr Li Tee Tan, consultant clinical oncologists, Oncology Centre, addenbrooke's Hospital, Cambridge University hospitals, NHS foundation trust, Cambridge, United Kingdom.</p> |
| August 2002- September 2005: | Assistant lecturer in Clinical Oncology, Faculty of Medicine, Menoufia University.  |
| August 2000- August 2002     | Specialist in Clinical Oncology, Faculty of Medicine, Menoufia University,  |
| 1997-2000:                   | Resident third Physician in Clinical Oncology Department, Menoufia University Hospitals, Egypt.   |
| Sept 1991- Aug 1997          | General Physician, Ministry of Health Hospitals, Menoufia Governorate.  |

### Clinical Experience (1997-2013)

- Radiation Therapy, EBRT various techniques with different tumour sites including work experience with treatment machines (LINAC; Cobalt 60) and treatment planning systems (CT, 3D, conformal) and IMRT and tomotherapy.
- Brachytherapy, particularly brachtherapy for gynaecological malignancies with related operative procedures, and IGBT.
- Chemotherapy administration and aftercare for both haematological and non-haematological malignancies.
- Palliative care.

### Oncology and radiotherapy

#### Training courses:

- Radiation protection course 2023
- ESTRO courses for breast , Gynae, lung, rectum radiotherapy contouring from 2012 to 2019 that was held in Egypt During BGICC and IGILUC
- IMRT, IGRT, Tomotherapy course in Nottingham radiotherapy centre from 23/3/2014 to 29/3/2014. Nottingham, UK.
- ESTRO Multidisciplinary management of breast cancer course. From 11 to 14 February 2012, Cairo, Egypt.
- Attended Cambridge image guided brachtherapy workshop for cervix cancer in January 2010, Cambridge, UK .
- Attended the British Paediatric radiotherapy course in November 2009, The British Medical Association (BMA), London, UK.
- Attended the Royal Marsden IMRT course “The image guided and intensity modulated radiotherapy course in clinical practice” that was held at The Institute of cancer Research, Chester Beaty Labs, from 5-7 February 2009, London, UK.
- Attended the 2009 brachytherapy course in Clatterbridge Centre of Oncology, Clatterbridge hospital, The Wirral, from 29-30 January 2009 Liverpool, UK.
- Attended the Practical management of Breast Cancer meeting at the Royal Society of Medicine – London, on the 10<sup>th</sup> of July 2008.

### **Teaching and Data Management Skills Acquired:**

- Assessment courses 4 levels in 2018-2019
- Academic program specification and program mapping in march, 2014
- Dale Carnegie Training high impact presentation from 22-23 of November 2012.
- Training courses ( staff development courses) attended at Menoufia University, (2000-2014).
- Teaching skills (3 week course, 2003).
- Development of statistical analysis skills using SPSS (from 10-19 May 2003).
- Introduction and Advanced courses in Microsoft Word, Excel, PowerPoint, database management with Microsoft Access, Presentation skills, writing a Thesis, Poster Presentation skills, Effective communication skills, time management, methods of scientific research.

**Teaching Experience:** My teaching commitments included bedside teaching of, junior house officers, nursing personnel, therapy radiographers, and post graduate students for master and MD degree in Clinical Oncology

**Medical assessment:** Assessment development course (advanced level) from faculty of medicine, Menoufia University from 25/12/2017 to 15/1/2018 for 23 hours  
OSCE and OSLE course 16 & 18 december 2018 from faculty of medicine, Menoufia University  
Assessment course (level C) 26, 30/12/2018, 2/1/2019 from faculty of medicine, Menoufia University  
Member of the master and MD exam committee over the last 5 years.

**Scientific Experience:** Supervision of several Master and MD thesis in clinical oncology.  
Board member of the Egyptian fellowship committee for radiotherapy.  
Committee member of the presidential initiatives for early detection and treatment of cancer.

**C) Awards & Grants:** Fund form STDF for research project for 3 years started 3/2023

Ideal physician in menoufia governerate from the National medical syndicate in march 2018

Grant from Ministry of Higher Education in Egypt as part of ParOwn project (partnership ownership agreement ) to help me perform research in collaboration with Dr Steve Chan at NUH Nottingham, UK (Jun 2007-Jan 2008).

Awarded the title of “Ideal Physician” in 1997, Medical Syndicate, Menoufia Branch.

## **Publications:**

### **Conference abstracts:**

1. Clinical relevance of BCL-x in patients with intermediate/ high grade non-Hodgkin's lymphomas. *Annals of oncology* vol 11, suppl 4, p 102 Abs 458P; Poster presentation at ESMO congress, Hamburg, 2000.
2. Small volume versus standard volume radiotherapy in invasive carcinoma of urinary bladder, ASCO 2005, abstract 4590.
3. Predictive markers for response to anthracycline based neo-adjuvant chemotherapy in locally advanced breast cancer (LAPC). A Mukherjee, M Shehata, et al, 2007, *Proceedings of NCRI cancer conference 2007*.
4. The basal phenotype (BP) is highly expressed in locally advanced breast cancer (LAPC) and predicts recurrence but not response to neo-adjuvant anthracycline based chemotherapy. A Mukherjee, M Shehata et al, 2007 (*Parallel session talk at the 10<sup>th</sup> Nottingham International breast cancer conference*). *European Journal of Cancer Supplements*, Volume 5, Issue 3, September 2007, Pages 16-17
5. Biomarkers predicting response to a novel oral taxane DJ-927 in metastatic breast cancer (MBC) Mukherjee et al, 2007 (*Parallel session talk at the 10<sup>th</sup> Nottingham International breast cancer conference*). *European Journal of Cancer Supplements*, Volume 5, Issue 3, September 2007, Page 17
6. Expression of thioredoxin system proteins in locally advanced breast cancer – correlations with response to anthracycline based chemotherapy (C/T). Lei Zhang et al, 2007 (*Parallel session talk at the 10<sup>th</sup> Nottingham International breast cancer conference*). *European Journal of Cancer Supplements*, Volume 5, Issue 3, September 2007, Page 16
7. Metastatic breast cancer (MBC) patients with severe hepatic or haematological dysfunction: efficacy and safety of a novel weekly regime of docetaxel. AS Dhabda, A Mukherjee, M A Shehata, R Molife, S Chan, 2007 (*Poster presentation at the 10<sup>th</sup> Nottingham International breast cancer Conference*).

8. A brief review of the dermatological and gastro-intestinal toxicities of Lapatinib. A. Mukherjee, M. A. Shehata, R. Sharma, AS Dhadda, S Chan, 2007 (*Parallel session talk at the 10<sup>th</sup> Nottingham International breast cancer conference*). European Journal of Cancer Supplements, Volume 5, Issue 3, September 2007, Pages 30-31
9. Human Leukocyte Antigen Class I Expression: A study in platinum sensitive and resistant ovarian cancer patients. M Shehata, A Mukherjee, S Deen, I Spendlove, LG Durrant and S Chan. Proceedings of the 1<sup>st</sup> Ovarian Cancer Action Conference, London, March, 2008.
10. Novel biomarkers in Ovarian Cancer. LG Durrant<sup>1\*</sup>, P Rolland, T Duncan, M Shehata, A Mukherjee, I Spendlove, I Scott, S Deen and Steve Chan Proceedings of the 1<sup>st</sup> Ovarian Cancer Action Conference, London, March, 2008.
11. Predictive markers of response to neo-adjuvant anthracycline based chemotherapy in locally advanced breast cancer (LAPC). A Mukherjee, M Shehata et al (2008) British Breast Group meeting, Cambridge, June 2008 (oral presentation).
12. Biomarkers predicting response to neoadjuvant anthracycline chemotherapy in locally advanced primary breast cancer- 2008 update A Mukherjee, M Shehata et al NCRI, Birmingham, 2008.
13. Is there are a role for immunotherapy in platinum sensitive and resistant ovarian cancer patients? Shehata M, Mukherjee et al, NCRI, Birmingham, 2008.
14. Altered expression of thioredoxin system proteins, in locally advanced breast cancer, predicts response to anthracyclin based chemotherapy. Caroline M Woolston, Lei Zhang, Ahmad Al-Attar, Mohamed Shehata, Ian Ellis, Stephen Y Chan, Stewart G Martin NCRI, Birmingham, 2009.
15. UK and European pattern of care in advanced breast cancer patients after exposure to anthracycline and taxane. Mohamed Shehata<sup>1</sup>, Ahmad Al-Attar<sup>1</sup>, Robert Leonard<sup>2</sup>, Rajiv Agrawal<sup>3</sup>, Greg Wilson<sup>4</sup>, Farhad Neave<sup>5</sup>, Martin Hogg<sup>6</sup>, Neville Davidson<sup>7</sup>, Amulya Chaturvedi<sup>8</sup>, Urmi Bapat<sup>9</sup> and Stephen Chan<sup>1</sup> NCRI, Birmingham, 2009.
16. Basal-like phenotype is a prognostic marker of locally advanced breast cancer but not a predictive marker of response to neoadjuvant anthracycline chemotherapy. M. Shehata, A. Mukherjee, P. Moseley, E. Rakha , I. Ellis, S. Chan, Oral presentation at the 1st BRITISH BREAST CANCER RESEARCH CONFERENCE WEDNESDAY 15 – FRIDAY 17 SEPTEMBER 2010 East Midlands Conference Centre, University Park, Nottingham.
17. Clinical Outcome and Survival of Head and Neck Cancer Patients Treated At Clinical Oncology Department, Menofia University, Khaled K. El Din, Mohamed

---

A. El-Fetouh, and Suzan Ahmed, UAE cancer congress 2014, Dubai ,from 30<sup>th</sup> October to 1<sup>st</sup> November, 2014

18. Concurrent hyper-fractionated radiotherapy with weekly gemcitabine is safe in locally advanced Head & Neck Cancer, E. A. Elkhoully<sup>1</sup>, M .A. El-Shenawy, N. M. Abd El-Bary, M. A. Shehata, UAE cancer congress 2014, , Dubai ,from 30<sup>th</sup> October to 1<sup>st</sup> November, 2014
19. Metronomic capecitabine maintenance in treatment of hepatocellular carcinoma after localised intervention. Suzan Ahmed, T Hashem, Mohamed A Shehata, Hager ElAgizy, Rehab Sayed, UAE cancer congress 2014, , Dubai ,from 30<sup>th</sup> October to 1<sup>st</sup> November, 2014
20. Impact of health care finance on health related quality of life (HRQOL) of chronic myeloid leukaemia (CML) patients. A single institute study. H.A.Alagizy , M.A.Shehata , E.T.Abdelrazek. The 5th Emirates Haematology Conference, Dubai, United Arab Emirates from 19 to 21 March 2015
21. The effect of hypofractionated radiotherapy on tumor control in patients with high risk breast cancer. mohamed a shehata, gamal saleh, mohamed elsharkawey, the 10<sup>th</sup> middle east best of San Antonio breast cancer symposium, Jeddah, Saudi Arabia, from 6 to 7 February, 2016
22. Does GLUT1 have a role in prognosis of breast carcinoma of Egyptian patients? Journal of clinical and diagnostic research. August 2018 accepted as poster presentation GBCC in march 2018.
23. Clinical value of CRP and erythrocyte sedimentation rate in advanced bladder cancer. Bladder conference 2018 and research in oncology July 2018.
24. Clinical recommendations in the management of advanced prostate cancer: International Gastrointestinal, Liver and Uro-oncology (IGILUC 2019) experts. World J Urol. 2020 Jul 8. doi: 10.1007/s00345-020-03328-3. Online ahead of print.PMID: 32643031
25. The prognostic value of Glasgow prognostic score in epithelial ovarian cancer. Menoufia Medical Journal 2020, 33:699–705

### Review articles:

1. Liposomal doxorubicin in breast cancer. M Shehata, A Mukherjee, R Sharma and S Chan. Future Science: Women's Health, 2007, Volume 3, Number 5, pp. 557-569(13)
2. Lapatinib: A Tyrosine Kinase Inhibitor (TKI) with a clinical role in Breast Cancer. A Mukherjee, AS Dhadda, M Shehata and S Chan. Expert Opinion in Pharmacotherapy, 2007, Sep; 8(13): 2189-204.



3. Reduced cardiotoxic profile of Myocet® (nonpegylated liposomal doxorubicin). M Shehata, A Mukherjee et al, Hospital Pharmacy, Europe, Issue 38, May/June 2008

**Peer-reviewed publications:**

1. Predictive markers of response to neoadjuvant chemotherapy in locally advanced breast cancer (LAPC)  
A Mukherjee, M Shehata, R Sharma, E Rakha, I Ellis, G Ball, BM Ball, ...  
Journal of Clinical Oncology 26 (15\_suppl), 581-581, 2008
2. A brief review of the dermatological and gastro-intestinal toxicities of Lapatinib  
A Mukherjee, MA Shehata, R Sharma, AS Dhadda, S Chan  
EJC Supplements 3 (5), 30-31, 2007
3. The basal phenotype (BP) is highly expressed in locally advanced breast cancer (LAPC) but does not predict response to neo-adjuvant anthracycline based chemotherapy  
A Mukherjee, MA Shehata, R Sharma, AS Dhadda, K Huber, C Paish, ...  
EJC Supplements 3 (5), 16-17, 2007
4. Biomarkers predicting response to a novel oral taxane DJ-927 in metastatic breast cancer (MBC)  
A Mukherjee, MA Shehata, K Huber, C Paish, I Ellis, R Oyama, SG Martin, ...  
EJC Supplements 3 (5), 17
5. Expression of thioredoxin system proteins in locally advanced breast cancer correlations with response to anthracycline based chemotherapy (C/T)  
L Zhang, S Chan, A Mukherjee, M Shehata, K Huber, I Ellis, P Patel, ...  
EJC Supplements 3 (5), 16, 2007
6. Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy. M Shehata, A Mukherjee, S Deen, A Al-Attar, LG Durrant and S Chan; British Journal of Cancer (2009) 101, 1321–1328
7. Role of PET/CT in Hodgkin's disease (HD) and Non-Hodgkin's lymphoma (NHL). Moustafa Radwan, Mohamed Shehata, Desmond Green; The Egyptian Journal of Radiology and Nuc. Med., vol. 40, No.3, (September): 829-838, 2009
8. T Cell Density and Location Can Influence the Prognosis of Ovarian Cancer Ahmad Al-Attar, Mohamed Shehata, Lindy Durrant, Paul Moseley, Suha Deen, Stephen Chan; Pathol Oncol Res. 2010 Sep;16(3):361-70
9. Human purinic/aprimidinic endonuclease (APE1) is a prognostic factor in ovarian, gastro-oesophageal and pancreato-biliary cancers. A Al-Attar, L Gossage, KR Fareed, M Shehata, M Mohammed, AM Zaitoun, I Soomro, DN Lobo, R Abbotts, S Chan and S Madhusudan; British Journal of Cancer (2010) 102, 704–709

10. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases – the UK experience S Sutherland, S Ashley, D Miles, S Chan, A Wardley, N Davidson, R Bhatti, M Shehata, H Nouras, T Camburn and SRD Johnston; Br J Cancer. 2010 Mar 16;102(6):995-1002
11. Topo2 $\alpha$  protein expression predicts response to anthracycline combination neoadjuvant chemotherapy in locally advanced primary breast cancer. A Mukherjee, M Shehata, P Moseley, E Rakha, I Ellis and S Chan; Br J Cancer. 2010 Dec 7;103(12):1794-800
12. Redox protein expression predicts progression-free and overall survival in ovarian cancer patients treated with platinum-based chemotherapy. Caroline M. Woolston a, Suha Deen , Ahmad Al-Attar , Mohamed Shehata , Stephen Y. Chan , Stewart G. Martin Free Radic Biol Med. 2010 Nov 1;49(8):1263-72
13. Calpain-1 expression is associated with relapse-free survival in breast cancer patients treated with trastuzumab following adjuvant chemotherapy Sarah J. Storr, Caroline M. Woolston, Fabricio F.T. Barros, Andrew R. Green, Mohamed Shehata, Stephen Y. Chan, Ian O. Ellis and Stewart G. Martin; International journal of cancer, (Epub ahead of print) 7 December, 2010
14. The prognostic and predictive power of redox protein expression for anthracycline-based chemotherapy response in locally advanced breast cancer Caroline M Woolston, Lei Zhang, Sarah J Storr, Ahmad Al-Attar, Mohamed Shehata, Ian O Ellis, Stephen Y Chan and Stewart G Martin. Modern Pathology (2012) 25, 1106–1116
15. Relationship of CK8/18 expression pattern to breast cancer immunohistochemical subtyping in Egyptian patients. Hayam A Aiad<sup>1</sup>, Rehab M Samaka<sup>1</sup>, Nancy Y Asaad<sup>1</sup>, Mona A Kandil<sup>1</sup>, Mohamed A Shehata<sup>2</sup> and Islam M Miligy<sup>1</sup>. *ecancer* 2014, 8:404 DOI: 10.3332/ecancer.2014.404
16. CD14<sup>+</sup> HLA-DR low/<sup>-</sup> monocytes as indicator of disease aggressiveness in B-cell non-Hodgkin lymphoma . K. A. KHALIFA\*, H. M. BADAWEY\*, W. M. RADWAN\*, M. A. SHEHATA †, M. A. BASSUONI\* the international journal of laboratory haematology. 2014
17. Management of ovarian cancer: Experience of a single Institution. Elkhoully. E.<sup>1</sup>, Abdelghany. A.<sup>1</sup>, Rageh. T <sup>2</sup> and Shehata. M.<sup>1</sup> Kasr El-aini J. Clin. Oncol. nucl. med. vol. 10, no. 1-2, Jan.-april. 2014
18. Clinical outcome and survival of head and neck cancer patients treated at Clinical Oncology Department, Menoufia University, Khaled K. El Din, Mohamed A. El-Fetouh, Suzan Ahmed, Amira H. Hegazy, Menoufia Medical Journal, 27:359–362, 2014
19. Overexpression of Carbonic Anhydrase IX is a Dismal Prognostic Marker in Breast Carcinoma in Egyptian Patients, Rehab M. Samaka, MD,\* Moshira M. Abd El-Wahed, MD,\* Dalia R. Al Sharaky, MD,\* AQ1 Mohamed A. Shehata, PhD,w Shaymaa Hegazy,\*

- and Mohammed A. Aleskandarany, PhD\*. Appl Immunohistochem Mol Morphol 2015; article in press
20. *Metronomic capecitabine as maintenance in treatment of hepatocellular carcinoma after localized intervention. Menoufia Medical Journal 2016, 29:443–448*
  21. *Androgen receptor expression in estrogen receptor-negative breast cancer. Menoufia Medical Journal 2018, 31:575–581*
  22. Clinical value of CRP and erythrocyte sedimentation rate in advanced bladder cancer. research in oncology July 2018, DOI: 10.21608/resoncol.2018.4152.1060
  23. Does GLUT-1 have a Role in Prognosis of Breast Carcinoma of Egyptian Patients? Journal of Clinical and Diagnostic Research. 2018 Aug, Vol-12(8): EC05-EC09
  24. Clinical recommendations in the management of advanced prostate cancer: International Gastrointestinal, Liver and Uro-oncology (IGILUC 2019) experts. World J Urol. 2020 Jul 8. doi: 10.1007/s00345-020-03328-3. Online ahead of print.PMID: 32643031
  25. The prognostic value of Glasgow prognostic score in epithelial ovarian cancer. Menoufia Medical Journal 2020, 33:699–705
  26. Value of l-alanyl-l-glutamine parenteral formula in patients with head and neck cancer receiving radiotherapy. *Menoufia Medical Journal 2020, 33:1379–1387*
  27. *Paclitaxel as a possible continuation maintenance therapy in advanced non-small cell lung cancer IJCBR Vol. 4(2): 133-141.*
  28. The first BGICC consensus and recommendations for breast cancer awareness, early detection and risk reduction in low-and middle-income countries and the MENA region. International journal of cancer 149 (3), 505-513
  29. *Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer. Cancers 2021, 13, 2262.*
  30. Mutation-Agnostic Detection of Colorectal Cancer Using Liquid Biopsy-Based Methylation-Specific Signatures. The Oncologist, 2023, 28, 368–372

## References:

**Dr Steve Chan**  
Consultant Oncologist  
Oncology Department  
Nottingham University Hospitals  
City Hospital Campus  
Hucknall Road  
NG5 1PB  
[Steve.chan@nuh.nhs.uk](mailto:Steve.chan@nuh.nhs.uk)

**Dr. Charlotte Coles**  
Consultant Oncologist  
Oncology Centre

Addenbrookes Hospital  
Cambridge University Hospitals  
Hills Road  
Cambridge  
CB2 2QQ  
Tel: +4401223 596182  
[charlotte.coles@addenbrookes.nhs.uk](mailto:charlotte.coles@addenbrookes.nhs.uk)

Dr. Li Tee Tan  
Consultant Oncologist  
Oncology Centre  
Addenbrooke's Hospital  
Cambridge University Hospitals  
Hills Road  
Cambridge  
CB2 2QQ  
Tel: +4401223 596182  
[litee.tan@addenbrookes.nhs.uk](mailto:litee.tan@addenbrookes.nhs.uk)

Dr. Khaled Kamal Eldeen Abd El-Aziz  
Professor and head of Clinical Oncology  
faculty of medicine  
Oncology department  
Faculty of Medicine  
Menoufia University  
Gamal Abdelnaser Street, Shebin Elkom  
Menoufia, 32511  
Egypt  
[Khaled22@gmail.com](mailto:Khaled22@gmail.com)  
+201001819199

Dr Tarek Hashem  
Professor of Clinical Oncology  
faculty of medicine  
Oncology department  
Faculty of Medicine  
Menoufia University  
Gamal Abdelnaser Street, Shebin Elkom  
Menoufia, 32511  
Egypt  
[thashem1@hotmail.com](mailto:thashem1@hotmail.com)  
Tel:+201222197793

**Membership of Clinical Societies:**

1. Egyptian Cancer Society
2. ESTRO
3. Fellow of the Royal college of radiologists (clinical Oncology)
4. ESMO

5. **Member** of the scientific committee for the presidential initiative for the prevention and treatment of cancer
6. **Breast and Gynaecology international cancer society (BGICS) (board member and radiotherapy Director)**